Research On The Correlation Between EGF, EGFR, PSA And Prostate Hyperplasia And Prostate Cancer

Objective:To evaluate the value of epidermal growth factor(EGF)in prostate hyperplasia and prostate cancer.Methods:The serum concentrations of EGF and prostate specific antigen(PSA)in 20 patients with prostate cancer,40 patients with prostate hyperplasia and 25 healthy controls were determined by enzyme-linked immunosorbent assay(ELISA)and electrochemiluminescence immunoassay;Expression by immunohistochemical method to detect EGFR in 40 cases of benign prostate hyperplasia,20 cases of prostate cancer tissues and 10 cases of normal prostate tissue,combined with clinical stage,Gleason score analysis.Results:(1)The level of serum EGF in patients with prostate cancer(median 10.50ng/mL)was higher than that in healthy controls(median0.75ng/mL,U = 0,P<0.05)and prostatic hyperplasia group(median 2.75 ng/mL,U = 3,P<0.05).(2)The level of serum PSA in patients with prostate cancer(median 116.56 ng/mL)was higher than that in healthy controls(median 1.01ng/mL,U=0,P<0.05)and prostatic hyperplasia group(median 5.92ng/mL,U = 0,P<0.05).(3)The serum EGF level in patients with benign prostatic hyperplasia(median 2.75 ng/mL)was higher than that in healthy controls(median 0.75 ng/mL,U = 47.5,P<0.05).(4)The serum PSA level in patients with benign prostatic hyperplasia(median 5.92 ng/mL)was higher than that in healthy controls(median 1.01 ng/mL,U = 41.5,P<0.05).(5)No significant correlation was found between serum EGF level and PSA level in patients with prostate cancer(r=-0.39,P-0.87>0.01).The level of serum EGF and PSA in patients with prostatic hyperplasia was positively correlated(r=0.744,P<0.01).The level of serum EGF and PSA in healthy control group was positively correlated(r=0.969,P<0.01).(6)The EGFR score in prostate cancer group was significantly higher than that in normal prostate group(U = 165,P=0.002<0.05)and benign prostatic hyperplasia group(U = 606.5,P<0.05).There was no significant difference of scores of EGFR in benign prostatic hyperplasia group and normalprostate group(U = 245,P=0.102>0.05).(7)The serum EGF concentration and EGFR score in the prostate cancer group were positively correlated(r=0.955,P<0.01(bilateral))and the serum EGF concentration and EGFR score in the benign prostatic hyperplasia group were also positively correlated(r=0.752,P<0.01(bilateral))(8)The serum level of EGF in the prostate cancer group had no significant correlation with clinical stage(H=1.593,P=0.451>0.05).The level of serum PSA and clinical stage was positively correlated(H=14.074,P=0.001<0.05).The EGFR score and clinical stage had no significant correlation(H=1.99,P=0.37>0.05).(9)There was no significant correlation between serum level of PSA in prostate cancer group and Gleason score(r=-0.42,P=0.859>0.05).The level of serum EGF and Gleason score was positively correlated(rEGF=0.864,P<0.01).EGFR score and Gleason score was positively correlated(rEGFR=0.9,P<0.01).Conclusions:(1)The level of serum EGF in patients with prostate cancer was significantly higher than that in benign prostatic hyperplasia patients and healthy control group,serum EGF concentration can be used as one of the auxiliary diagnosis of prostate cancer index.(2)The level of serum EGF and EGFR scores were correlated with Gleason score,illustrates its histological grade may be closely related to.